nach oben

European Journal of Nutrition

Erschienen in:

04.01.2022 | Original Contribution

Lactobacillus casei Zhang exerts anti-obesity effect to obese glut1 and gut-specific-glut1 knockout mice via gut microbiota modulation mediated different metagenomic pathways

verfasst von: Qiuwen He, Yong Zhang, Da Ma, Weiqin Zhang, Heping Zhang

Erschienen in: European Journal of Nutrition | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Obesity is a major risk factor for various metabolic diseases, including metabolic syndrome and type-2 diabetes. Glucose transporter 1 (GLUT1) impairment has been proposed as a mechanism of fat accumulation and glucose tolerance. Our aims were to determine the role of intestinal epithelial glut1 activity in obesity and the mechanism of anti-obesity effect of Lactobacillus casei Zhang (LCZ) intervention in the absence of gut villi-specific glut1 expression.

Methods

This study compared the body weight, intestinal microbiota perturbations, fat mass accumulation, and glucose tolerance (by oral glucose tolerance test) between high-fat diet fed villi-specific glut1 knockout (KO) mice and control mice (glut1 flox/flox) with/without LCZ intervention. The intestinal microbiota was evaluated by metagenomic sequencing.

Results

Our results showed that villi-specific glut1 KO mice had more fat deposition at the premetaphase stage, impaired glucose tolerance, and obvious alterations in gut microbiota compared to control mice. Probiotic administration significantly lowered the body weight, the weights of mesenteric and perirenal white adipose tissues (WAT), and mediated gut microbiota modulation in both types of KO and control mice. The species Barnesiella intestinihominis and Faecalibaculum rodentium might contribute to fasting fat mass accumulation associated with gut-specific glut1 inactivation, while the probiotic-mediated anti-obesity effect was linked to members of the Bacteroides genera, Odoribacter genera and Alistipes finegoldii.

Conclusion

Our study demonstrated that abrogating gut epithelial GLUT1 activity affected the gut microbiota, fat mass accumulation, and glucose tolerance; and LCZ administration reduced fat mass accumulation and central obesity.

Nur mit Berechtigung zugänglich

Reilly JJ, El-Hamdouchi A, Diouf A et al (2018) Determining the worldwide prevalence of obesity. Lancet 391:1773–1774. https://doi.org/10.1016/S0140-6736(18)30794-3CrossRefPubMed

Sahakyan KR, Somers VK, Rodriguez-Escudero JP et al (2015) Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med 163:827–835. https://doi.org/10.7326/M14-2525CrossRefPubMedPubMedCentral

Wang Y, Rimm EB, Stampfer MJ et al (2005) Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 81:555–563. https://doi.org/10.1093/ajcn/81.3.555CrossRefPubMed

Lee M-J, Pramyothin P, Karastergiou K, Fried SK (2014) Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta 1842:473–481. https://doi.org/10.1016/j.bbadis.2013.05.029CrossRefPubMed

Liu KH, Chan YL, Chan JCN et al (2006) Mesenteric fat thickness as an independent determinant of fatty liver. Int J Obes (Lond) 30:787–793. https://doi.org/10.1038/sj.ijo.0803201CrossRef

Liu KH, Chan YL, Chan WB et al (2006) Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness. Diabetes Care 29:379–384. https://doi.org/10.2337/diacare.29.02.06.dc05-1578CrossRefPubMed

Borruel S, Fernández-Durán E, Alpañés M et al (2013) Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 98:1254–1263. https://doi.org/10.1210/jc.2012-3698CrossRefPubMed

Liu KH, Chan YL, Chan WB et al (2003) Sonographic measurement of mesenteric fat thickness is a good correlate with cardiovascular risk factors: comparison with subcutaneous and preperitoneal fat thickness, magnetic resonance imaging and anthropometric indexes. Int J Obes Relat Metab Disord 27:1267–1273. https://doi.org/10.1038/sj.ijo.0802398CrossRefPubMed

Lam YY, Ha CWY, Campbell CR et al (2012) Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0034233CrossRefPubMedPubMedCentral

10.

Lee M-J, Wu Y, Fried SK (2013) Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 34:1–11. https://doi.org/10.1016/j.mam.2012.10.001CrossRefPubMed

11.

DeBosch BJ, Kluth O, Fujiwara H et al (2014) Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun 5:4642. https://doi.org/10.1038/ncomms5642CrossRefPubMed

12.

Longo M, Zatterale F, Naderi J et al (2019) Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci. https://doi.org/10.3390/ijms20092358CrossRefPubMedPubMedCentral

13.

Yang Q, Graham TE, Mody N et al (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–362. https://doi.org/10.1038/nature03711CrossRefPubMed

14.

Massier L, Chakaroun R, Tabei S et al (2020) Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes. Gut 69:1796–1806. https://doi.org/10.1136/gutjnl-2019-320118CrossRefPubMed

15.

Wueest S, Item F, Lucchini FC et al (2016) Mesenteric fat lipolysis mediates obesity-associated hepatic steatosis and insulin resistance. Diabetes 65:140–148. https://doi.org/10.2337/db15-0941CrossRefPubMed

16.

Klepper J, Akman C, Armeno M et al (2020) Glut1 Deficiency Syndrome (Glut1DS): state of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 5:354–365. https://doi.org/10.1002/epi4.12414CrossRefPubMedPubMedCentral

17.

Koch H, Weber YG (2019) The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav 91:90–93. https://doi.org/10.1016/j.yebeh.2018.06.010CrossRefPubMed

18.

Ivanova N, Peycheva V, Kamenarova K et al (2018) Three novel SLC2A1 mutations in Bulgarian patients with different forms of genetic generalized epilepsy reflecting the clinical and genetic diversity of GLUT1-deficiency syndrome. Seizure 54:41–44. https://doi.org/10.1016/j.seizure.2017.11.014CrossRefPubMed

19.

Wang J, Ye C, Chen C et al (2017) Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget 8:16875–16886. https://doi.org/10.1863/oncotarget.15171CrossRefPubMedPubMedCentral

20.

Chari M, Yang CS, Lam CKL et al (2011) Glucose transporter-1 in the hypothalamic glial cells mediates glucose sensing to regulate glucose production in vivo. Diabetes 60:1901–1906. https://doi.org/10.2337/db11-0120CrossRefPubMedPubMedCentral

21.

Indian Council of Medical Research Task Force, Co-ordinating Unit ICMR, Co-ordinating Unit DBT (2011) ICMR-DBT guidelines for evaluation of probiotics in food. Indian J Med Res 134:22–25

22.

Wu S, Liu Y, Duan Y et al (2018) Intestinal toxicity of deoxynivalenol is limited by supplementation with Lactobacillus plantarum JM113 and consequentially altered gut microbiota in broiler chickens. J Anim Sci Biotechnol 9:74. https://doi.org/10.1186/s40104-018-0286-5CrossRefPubMedPubMedCentral

23.

Kim ST, Kim HB, Lee KH et al (2012) Steam-dried ginseng berry fermented with Lactobacillus plantarum controls the increase of blood glucose and body weight in type 2 obese diabetic db/db mice. J Agric Food Chem 60:5438–5445. https://doi.org/10.1021/jf300460gCrossRefPubMed

24.

Zhang Y, Wang L, Zhang J et al (2014) Probiotic Lactobacillus casei Zhang ameliorates high-fructose-induced impaired glucose tolerance in hyperinsulinemia rats. Eur J Nutr 53:221–232. https://doi.org/10.1007/s00394-013-0519-5CrossRefPubMed

25.

Zhong Z, Zhang W, Du R et al (2012) Lactobacillus casei Zhang stimulates lipid metabolism in hypercholesterolemic rats by affecting gene expression in the liver. Eur J Lipid Sci Technol. https://doi.org/10.1002/ejlt.201100118CrossRef

26.

Young CD, Lewis AS, Rudolph MC et al (2011) Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS ONE 6:e23205. https://doi.org/10.1371/journal.pone.0023205CrossRefPubMedPubMedCentral

27.

Franzosa EA, McIver LJ, Rahnavard G et al (2018) Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 15:962–968. https://doi.org/10.1038/s41592-018-0176-yCrossRefPubMedPubMedCentral

28.

Ke X, Walker A, Haange S-B et al (2019) Synbiotic-driven improvement of metabolic disturbances is associated with changes in the gut microbiome in diet-induced obese mice. Mol Metab 22:96–109. https://doi.org/10.1016/j.molmet.2019.01.012CrossRefPubMedPubMedCentral

29.

Zhang Y, Hou Q, Ma C et al (2020) Lactobacillus casei protects dextran sodium sulfate- or rapamycin-induced colonic inflammation in the mouse. Eur J Nutr 59:1443–1451. https://doi.org/10.1007/s00394-019-02001-9CrossRefPubMed

30.

Park S, Ji Y, Jung H-Y et al (2017) Lactobacillus plantarum HAC01 regulates gut microbiota and adipose tissue accumulation in a diet-induced obesity murine model. Appl Microbiol Biotechnol 101:1605–1614. https://doi.org/10.1007/s00253-016-7953-2CrossRefPubMed

31.

Szeto HH, Liu S, Soong Y et al (2016) Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int 90:997–1011. https://doi.org/10.1016/j.kint.2016.06.013CrossRefPubMed

32.

Zhang Y, Sun Q, Li Z et al (2019) Fermented soybean powder containing Bacillus subtilis SJLH001 protects against obesity in mice by improving transport function and inhibiting angiogenesis. J Funct Foods 59:60–70. https://doi.org/10.1016/j.jff.2019.05.033CrossRef

33.

Patching SG (2017) Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol 54:1046–1077. https://doi.org/10.1007/s12035-015-9672-6CrossRefPubMed

34.

Cani PD, Osto M, Geurts L, Everard A (2012) Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 3:279–288. https://doi.org/10.4161/gmic.19625CrossRefPubMedPubMedCentral

35.

Cani PD, Amar J, Iglesias MA et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761–1772. https://doi.org/10.2337/db06-1491CrossRefPubMed

36.

Henao-Mejia J, Elinav E, Jin C et al (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179–185. https://doi.org/10.1038/nature10809CrossRefPubMedPubMedCentral

37.

Le Roy T, Llopis M, Lepage P et al (2013) Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62:1787–1794. https://doi.org/10.1136/gutjnl-2012-303816CrossRefPubMed

38.

Tirosh A, Calay ES, Tuncman G et al (2019) The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aav0120CrossRefPubMed

39.

Zagato E, Pozzi C, Bertocchi A et al (2020) Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol 5:511–524. https://doi.org/10.1038/s41564-019-0649-5CrossRefPubMedPubMedCentral

40.

Magne F, Gotteland M, Gauthier L et al (2020) The Firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients. https://doi.org/10.3390/nu12051474CrossRefPubMedPubMedCentral

41.

Gauffin Cano P, Santacruz A, Moya Á, Sanz Y (2012) Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PLoS ONE 7:e41079. https://doi.org/10.1371/journal.pone.0041079CrossRefPubMedPubMedCentral

42.

Yang J-Y, Lee Y-S, Kim Y et al (2017) Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol 10:104–116. https://doi.org/10.1038/mi.2016.42CrossRefPubMed

43.

Verdam FJ, Fuentes S, de Jonge C et al (2013) Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring) 21:E607-615. https://doi.org/10.1002/oby.20466CrossRef

44.

Liu H-Y, Walden TB, Ahl D et al (2019) High-fat diet enriched with bilberry modifies colonic mucus dynamics and restores marked alterations of gut microbiome in rats. Mol Nutr Food Res 63:e1900117. https://doi.org/10.1002/mnfr.201900117CrossRefPubMed

45.

Radka C, Frank M, Rock C, Yao J (2019) Fatty acid activation and utilization by Alistipes finegoldii, a representative Bacteroidetes resident of the human gut microbiome. Mol Microbiol. https://doi.org/10.1111/mmi.14445CrossRef

46.

Lee C, Hong SN, Paik NY et al (2019) CD1d modulates colonic inflammation in NOD2-/- mice by altering the intestinal microbial composition comprising Acetatifactor muris. J Crohns Colitis 13:1081–1091. https://doi.org/10.1093/ecco-jcc/jjz025CrossRefPubMed

47.

Pfeiffer N, Desmarchelier C, Blaut M et al (2012) Acetatifactor muris gen. nov., sp. nov., a novel bacterium isolated from the intestine of an obese mouse. Arch Microbiol 194:901–907. https://doi.org/10.1007/s00203-012-0822-1CrossRefPubMed

48.

Mondot S, Kang S, Furet JP et al (2011) Highlighting new phylogenetic specificities of Crohn’s disease microbiota. Inflamm Bowel Dis 17:185–192. https://doi.org/10.1002/ibd.21436CrossRefPubMed

49.

Hiippala K, Barreto G, Burrello C et al (2020) Novel odoribacter splanchnicus strain and its outer membrane vesicles exert immunoregulatory effects in vitro. Front Microbiol 11:575455. https://doi.org/10.3389/fmicb.2020.575455CrossRefPubMedPubMedCentral

50.

Geurts L, Lazarevic V, Derrien M et al (2011) Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2:149. https://doi.org/10.3389/fmicb.2011.00149CrossRefPubMedPubMedCentral

51.

Sun J, Qiao Y, Qi C et al (2016) High-fat-diet-induced obesity is associated with decreased antiinflammatory Lactobacillus reuteri sensitive to oxidative stress in mouse Peyer’s patches. Nutrition 32:265–272. https://doi.org/10.1016/j.nut.2015.08.020CrossRefPubMed

Titel: Lactobacillus casei Zhang exerts anti-obesity effect to obese glut1 and gut-specific-glut1 knockout mice via gut microbiota modulation mediated different metagenomic pathways
verfasst von: Qiuwen He
Yong Zhang
Da Ma
Weiqin Zhang
Heping Zhang
Publikationsdatum: 04.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 4/2022
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-021-02764-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Lactobacillus casei Zhang exerts anti-obesity effect to obese glut1 and gut-specific-glut1 knockout mice via gut microbiota modulation mediated different metagenomic pathways

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Probiotic supplementation demonstrates therapeutic potential in treating gut dysbiosis and improving neurocognitive function in age-related dementia

Correction to: Reported organic food consumption and metabolic syndrome in older adults: cross‑sectional and longitudinal analyses

Effect of oat supplementation interventions on cardiovascular disease risk markers: a systematic review and meta-analysis of randomized controlled trials

Characterization of metabolites and biomarkers for the probiotic effects of Clostridium cochlearium on high-fat diet-induced obese C57BL/6 mice

Effect of maternal curcumin supplementation on intestinal damage and the gut microbiota in male mice offspring with intra-uterine growth retardation

Correction to: Therapy with probiotics and synbiotics for polycystic ovarian syndrome: a systematic review and meta‑analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

Update Innere Medizin